REFERENCES
1. Kleiner DE, Chalasani NP, Lee WM, et al.; Drug-Induced Liver Injury Network (DILIN). Hepatic histological findings in suspected drug-induced liver injury: systematic evaluation and clinical associations. Hepatology. 2014;59:661-70.
2. Tian QJ, Zhao XY, Wang Y, et al. Histologic pattern is better correlated with clinical outcomes than biochemical classification in patients with drug-induced liver injury. Mod Pathol. 2019;32:1795-805.
3. Andrade RJ, Chalasani N, Björnsson ES, et al. Drug-induced liver injury. Nat Rev Dis Primers. 2019;5:58.
4. Zhao J, van Mierlo KMC, Gómez-Ramírez J, et al.; Chemotherapy-Associated Liver Injury (CALI) consortium. Systematic review of the influence of chemotherapy-associated liver injury on outcome after partial hepatectomy for colorectal liver metastases. Br J Surg. 2017;104:990-1002.
5. Zhu C, Ren X, Liu D, Zhang C. Oxaliplatin-induced hepatic sinusoidal obstruction syndrome. Toxicology. 2021;460:152882.
6. Tabassum H, Waseem M, Parvez S, Qureshi MI. Oxaliplatin-induced oxidative stress provokes toxicity in isolated rat liver mitochondria. Arch Med Res. 2015;46:597-603.
7. Kim HP, Navarro V, Zacks S, Odin J, Kleiner DE, Hayashi PH; Drug-Induced Liver Injury Network Investigators. The clinical spectrum and diagnosis of oxaliplatin liver injury in the era of nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2021;19:2199-201.
8. Mahlmann JC, Wirth TC, Hartleben B, et al. Chemotherapy and hepatic steatosis: impact on postoperative morbidity and survival after liver resection for colorectal liver metastases. Visc Med. 2021;37:198-205.
9. Vigano L, De Rosa G, Toso C, et al. Reversibility of chemotherapy-related liver injury. J Hepatol. 2017;67:84-91.
10. López-Pascual E, Rienda I, Perez-Rojas J, et al. Drug-induced fatty liver disease (DIFLD): a comprehensive analysis of clinical, biochemical, and histopathological data for mechanisms identification and consistency with current adverse outcome pathways. Int J Mol Sci. 2024;25:5203.
11. Fernandez FG, Ritter J, Goodwin JW, Linehan DC, Hawkins WG, Strasberg SM. Effect of steatohepatitis associated with irinotecan or oxaliplatin pretreatment on resectability of hepatic colorectal metastases. J Am Coll Surg. 2005;200:845-53.
12. Vauthey JN, Pawlik TM, Ribero D, et al. Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol. 2006;24:2065-72.
13. Morawska I, Pasicz K, Cieszanowski A. Biomarkers of systemic treatment response: MR images of intratumoral fat deposition in colorectal liver metastases (CRLM) after chemotherapy. Int J Colorectal Dis. 2024;39:185.
14. Lin Y, Li Y, Hu X, et al. The hepatoprotective role of reduced glutathione and its underlying mechanism in oxaliplatin-induced acute liver injury. Oncol Lett. 2018;15:2266-72.
15. Lu Y, Wu S, Xiang B, Li L, Lin Y. Curcumin attenuates oxaliplatin-induced liver injury and oxidative stress by activating the Nrf2 pathway. Drug Des Devel Ther. 2020;14:73-85.
16. Aloia T, Sebagh M, Plasse M, et al. Liver histology and surgical outcomes after preoperative chemotherapy with fluorouracil plus oxaliplatin in colorectal cancer liver metastases. J Clin Oncol. 2006;24:4983-90.
17. Rubbia-Brandt L, Lauwers GY, Wang H, Majno PE, Tanabe K, Zhu AX, et al. Sinusoidal obstruction syndrome and nodular regenerative hyperplasia are frequent oxaliplatin-associated liver lesions and partially prevented by bevacizumab in patients with hepatic colorectal metastasis. Histopathology. 2010;56:430-9.
18. Makowiec F, Möhrle S, Neeff H, et al. Chemotherapy, liver injury, and postoperative complications in colorectal liver metastases. J Gastrointest Surg. 2011;15:153-64.
19. Li M, Luo Q, Tao Y, Sun X, Liu C. Pharmacotherapies for drug-induced liver injury: a current literature review. Front Pharmacol. 2021;12:806249.
20. Gong X, Li T, Wan R, Sha L. Cordycepin attenuates high-fat diet-induced non-alcoholic fatty liver disease via down-regulation of lipid metabolism and inflammatory responses. Int Immunopharmacol. 2021;91:107173.
21. Lan T, Yu Y, Zhang J, et al. Cordycepin ameliorates nonalcoholic steatohepatitis by activation of the AMP-activated protein kinase signaling pathway. Hepatology. 2021;74:686-703.
22. Chen Y, Wang P, Zhang M, Yang H, Liang B. Mechanism analysis of the effect of cordycepin on colorectal cancer via network pharmacology and experiment. Comb Chem High Throughput Screen. 2026;29:411-22.
23. Rui F, Yeo YH, Xu L, et al. Development of a machine learning-based model to predict hepatic inflammation in chronic hepatitis B patients with concurrent hepatic steatosis: a cohort study. EClinicalMedicine. 2024;68:102419.
24. Mudd TW, Guddati AK. Management of hepatotoxicity of chemotherapy and targeted agents. Am J Cancer Res. 2021;11:3461-74.
25. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209-49.
26. Keizman D, Maimon N, Ish-Shalom M, Buchbut D, Inbar M, Klein B, et al. An animal model for chemotherapy-associated steatohepatitis and its prevention by the oral administration of fatty acid bile acid conjugate. Cancer. 2010;116:251-5.
27. Schwingel TE, Klein CP, Nicoletti NF, et al. Effects of the compounds resveratrol, rutin, quercetin, and quercetin nanoemulsion on oxaliplatin-induced hepatotoxicity and neurotoxicity in mice. Naunyn Schmiedebergs Arch Pharmacol. 2014;387:837-48.
28. Lu Y, Lin Y, Huang X, Wu S, Wei J, Yang C. Oxaliplatin aggravates hepatic oxidative stress, inflammation and fibrosis in a non‑alcoholic fatty liver disease mouse model. Int J Mol Med. 2019;43:2398-408.
29. Green CJ, Parry SA, Gunn PJ, et al. Studying non-alcoholic fatty liver disease: the ins and outs of in vivo, ex vivo and in vitro human models. Horm Mol Biol Clin Investig. 2018;41:/j/hmbci.
30. Limanaqi F, Busceti CL, Biagioni F, et al. Cell clearing systems as targets of polyphenols in viral infections: potential implications for COVID-19 pathogenesis. Antioxidants. 2020;9:1105.
31. Ashraf SA, Elkhalifa AEO, Siddiqui AJ, et al. Cordycepin for health and wellbeing: a potent bioactive metabolite of an entomopathogenic Cordyceps medicinal fungus and its nutraceutical and therapeutic potential. Molecules. 2020;25:2735.
32. Qing R, Huang Z, Tang Y, Xiang Q, Yang F. Cordycepin negatively modulates lipopolysaccharide-induced cytokine production by up-regulation of heme oxygenase-1. Int Immunopharmacol. 2017;47:20-7.
33. Cao T, Xu R, Xu Y, Liu Y, Qi D, Wan Q. The protective effect of Cordycepin on diabetic nephropathy through autophagy induction in vivo and in vitro. Int Urol Nephrol. 2019;51:1883-92.
34. Zhong LP, Li J, Wang FZ, Zhu HB, Hou XJ. Protective effect and underlying mechanism of cordycepin on non-alcoholic fatty liver in ob/ob mice. Yao Xue Xue Bao 2017;52:106-12.
35. Caldwell RB, Toque HA, Narayanan SP, Caldwell RW. Arginase: an old enzyme with new tricks. Trends Pharmacol Sci. 2015;36:395-405.
36. Suschek CV, Schnorr O, Hemmrich K, et al. Critical role of L-arginine in endothelial cell survival during oxidative stress. Circulation. 2003;107:2607-14.
37. Boga S, Alkim H, Koksal AR, et al. Increased plasma levels of asymmetric dimethylarginine in nonalcoholic fatty liver disease: relation with insulin resistance, inflammation, and liver histology. J Investig Med. 2015;63:871-7.
38. Abu-Serie MM, El-Gamal BA, El-Kersh MA, El-Saadani MA. Investigation into the antioxidant role of arginine in the treatment and the protection for intralipid-induced non-alcoholic steatohepatitis. Lipids Health Dis. 2015;14:128.
39. Yun C, Yan S, Liao B, et al. The microbial metabolite agmatine acts as an FXR agonist to promote polycystic ovary syndrome in female mice. Nat Metab. 2024;6:947-62.
40. Kasumov T, Edmison JM, Dasarathy S, Bennett C, Lopez R, Kalhan SC. Plasma levels of asymmetric dimethylarginine in patients with biopsy-proven nonalcoholic fatty liver disease. Metabolism. 2011;60:776-81.
41. Chávez-Talavera O, Tailleux A, Lefebvre P, Staels B. Bile acid control of metabolism and inflammation in obesity, type 2 diabetes, dyslipidemia, and nonalcoholic fatty liver disease. Gastroenterology. 2017;152:1679-94.e3.
42. Yamamoto S, Sato I, Fukuhama N, et al. Bile acids aggravate nonalcoholic steatohepatitis and cardiovascular disease in SHRSP5/Dmcr rat model. Exp Mol Pathol. 2020;114:104437.
43. Zhang Z, He C, Zhang L, et al. Alpha-ketoglutarate affects murine embryo development through metabolic and epigenetic modulations. Reproduction. 2019;158:123-33.
44. Zhang ZH, Yang CT, Su XR, et al. CCK1R2R-/- ameliorates myocardial damage caused by unpredictable stress via altering fatty acid metabolism. Stress. 2023;26:2254566.
45. Liu G, Lu J, Sun W, et al. Alpha-ketoglutaric acid attenuates oxidative stress and modulates mitochondrial dynamics and autophagy of spleen in a piglet model of lipopolysaccharide-induced sepsis. Free Radic Biol Med. 2024;214:80-6.
46. Cheng D, Zhang M, Zheng Y, et al. α-Ketoglutarate prevents hyperlipidemia-induced fatty liver mitochondrial dysfunction and oxidative stress by activating the AMPK-pgc-1α/Nrf2 pathway. Redox Biol. 2024;74:103230.
